A stock that yields 69% a year? Really?

From Investing Daily | Ad

In today’s helter-skelter market, most investors would be happy with stocks yielding 4% or 5%. But they’d be setting their sights too low. Because I’ve built a portfolio that pays us a 69% cash on cash return — with no leverage, options, or gimmicks.

Details here.

CARA Insider Trading (Cara Therapeutics)

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.20%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $1,876,951.66

Cara Therapeutics Insider Trading History Chart

Cara Therapeutics Share Price & Price History

^$14.45

▼ -0.1 (-0.69%)

As of 06/21/2021 03:55 PM ET

Days: 30 | 90 | 365

Learn How to Analyze Your Market and Trading Plan

From RJO Futures | Ad

Custom-design an options strategy to fit your market outlook. This guide goes beyond the basics to help you understand how to evaluate a strategy’s risk and reward. Start with your market outlook, then hone in on your strategy based on the risk you’re willing to take.

Download Your FREE Options Trading Strategy Guide today!

Cara Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/7/2021	Martin Vogelbaum	Director	Sell	8,640	$13.05	$112,752.00	28,800
4/21/2021	Joana Goncalves	Insider	Sell	3,000	$27.63	$82,890.00	43,610
3/22/2021	Joana Goncalves	Insider	Sell	3,000	$19.65	$58,950.00	30,610
3/5/2021	Derek T Chalmers	CEO	Sell	3,103	$17.98	$55,791.94	953,614
3/5/2021	Frederique Ph.D. Menzaghi	SVP	Sell	3,358	$17.98	$60,376.84	122,677
3/5/2021	Scott Terrillion	Insider	Sell	3,090	$17.98	$55,558.20	54,432
2/25/2021	Derek T Chalmers	CEO	Sell	11,729	$19.33	$226,721.57	955,343
2/25/2021	Frederique Ph.D. Menzaghi	SVP	Sell	5,003	$19.33	$96,707.99	117,680
2/25/2021	Scott Terrillion	Insider	Sell	4,004	$19.33	$77,397.32	48,436
1/21/2021	Joana Goncalves	Insider	Sell	2,000	$20.12	$40,240.00	28,075
12/30/2020	Derek T Chalmers	CEO	Sell	6,078	$15.30	$92,993.40	936,593
12/30/2020	Frederique Ph.D. Menzaghi	SVP	Sell	2,812	$15.30	$43,023.60	109,680
12/30/2020	Scott Terrillion	Insider	Sell	1,946	$15.30	$29,773.80	42,436
12/28/2020	Derek T Chalmers	CEO	Sell	5,000	$16.00	$80,000.00	947,671
12/21/2020	Joana Goncalves	Insider	Sell	2,000	$15.00	$30,000.00	27,373
12/16/2020	Derek T Chalmers	CEO	Sell	5,000	$14.95	$74,750.00	928,921
12/10/2020	Derek T Chalmers	CEO	Sell	7,500	$15.29	$114,675.00	933,921
11/23/2020	Joana Goncalves	Insider	Sell	2,000	$15.31	$30,620.00	29,373
11/19/2020	Christopher Posner	Director	Sell	2,000	$15.82	$31,640.00	11,200
11/17/2020	Derek T Chalmers	CEO	Sell	11,799	$16.00	$188,784.00	941,421
11/17/2020	Martin Vogelbaum	Director	Sell	6,000	$16.09	$96,540.00	14,400
11/10/2020	Joana Goncalves	Insider	Sell	2,000	$15.00	$30,000.00	31,373
10/20/2020	Joana Goncalves	Insider	Sell	2,000	$15.00	$30,000.00	33,373
9/3/2020	Derek T Chalmers	CEO	Sell	3,201	$16.00	$51,216.00	953,220
7/1/2020	Derek T Chalmers	CEO	Sell	5,000	$17.11	$85,550.00	961,421
6/12/2020	Joana Goncalves	Insider	Sell	10,627	$15.05	$159,936.35	46,000
6/3/2020	Derek T Chalmers	CEO	Sell	4,300	$16.01	$68,843.00	970,721
6/1/2020	Derek T Chalmers	CEO	Sell	700	$16.00	$11,200.00	970,721
6/1/2020	Jeffrey L Ives	Director	Sell	1,000	$16.00	$16,000.00	7,000
5/22/2020	Derek T Chalmers	CEO	Sell	371	$16.00	$5,936.00	975,292
5/20/2020	Derek T Chalmers	CEO	Sell	1,200	$16.00	$19,200.00	975,292
5/12/2020	Derek T Chalmers	CEO	Sell	4,929	$16.00	$78,864.00	976,492
5/12/2020	Jeffrey L Ives	Director	Sell	2,500	$16.00	$40,000.00	8,500
4/21/2020	Derek T Chalmers	CEO	Sell	6,348	$15.56	$98,774.88	987,769
4/21/2020	Frederique Ph.D. Menzaghi	SVP	Sell	12,894	$15.58	$200,888.52	117,386
4/21/2020	Jeffrey L Ives	Director	Sell	2,500	$16.00	$40,000.00	8,500
4/21/2020	Scott Terrillion	Insider	Sell	2,721	$15.56	$42,338.76	41,103
3/4/2020	Jeffrey L Ives	Director	Sell	2,500	$16.00	$40,000.00	8,500
1/2/2020	Derek T Chalmers	CEO	Sell	10,000	$16.05	$160,500.00	917,769
1/2/2020	Jeffrey L Ives	Director	Sell	2,500	$16.13	$40,325.00	8,500
12/4/2019	Derek T Chalmers	CEO	Sell	10,699	$17.05	$182,417.95	918,468
12/4/2019	Mani Mohindru	CFO	Sell	4,755	$17.05	$81,072.75	22,196
12/4/2019	Scott Terrillion	Insider	Sell	3,980	$17.05	$67,859.00	20,749
12/2/2019	Derek T Chalmers	CEO	Sell	10,000	$25.79	$257,900.00	918,468
12/2/2019	Jeffrey L Ives	Director	Sell	2,500	$25.83	$64,575.00	8,500
11/1/2019	Derek T Chalmers	CEO	Sell	5,000	$20.79	$103,950.00	928,468
11/1/2019	Jeffrey L Ives	Director	Sell	2,500	$20.68	$51,700.00	8,500
10/25/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$19.91	$79,640.00	63,886
10/18/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$19.33	$77,320.00	67,886
10/11/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$18.70	$74,800.00	71,886
10/4/2019	Frederique Ph.D. Menzaghi	SVP	Sell	4,000	$19.19	$76,760.00	75,886
10/1/2019	Derek T Chalmers	CEO	Sell	10,000	$18.28	$182,800.00	933,468
10/1/2019	Jeffrey L Ives	Director	Sell	2,500	$18.21	$45,525.00	8,500
9/3/2019	Derek T Chalmers	CEO	Sell	5,000	$23.26	$116,300.00	943,468
9/3/2019	Frederique Ph.D. Menzaghi	SVP	Sell	20,000	$22.92	$458,400.00	79,886
9/3/2019	Jeffrey L Ives	Director	Sell	2,500	$23.31	$58,275.00	8,500
8/1/2019	Derek T Chalmers	CEO	Sell	10,000	$23.27	$232,700.00	948,468
8/1/2019	Frederique Ph.D. Menzaghi	SVP	Sell	20,000	$23.24	$464,800.00	99,886
8/1/2019	Jeffrey L Ives	Director	Sell	2,500	$23.24	$58,100.00	8,500
7/17/2019	Frederique Ph.D. Menzaghi	Insider	Sell	8,996	$27.50	$247,390.00	119,886
7/15/2019	Mani Mohindru	CFO	Sell	37,431	$25.00	$935,775.00	51,294
7/1/2019	Frederique Ph.D. Menzaghi	Insider	Sell	20,000	$21.90	$438,000.00	128,882
7/1/2019	Jeffrey L Ives	Director	Sell	2,500	$21.75	$54,375.00	8,500
5/29/2019	Derek T Chalmers	CEO	Sell	5,528	$21.42	$118,409.76	963,996
5/29/2019	Frederique Ph.D. Menzaghi	Insider	Sell	11,397	$21.19	$241,502.43	160,279
5/29/2019	Mani Mohindru	CFO	Sell	2,496	$21.39	$53,389.44	16,359
3/13/2019	Frederique Ph.D. Menzaghi	Insider	Sell	20,000	$18.65	$373,000.00	139,582
3/13/2019	Mani Mohindru	CFO	Sell	16,041	$19.12	$306,703.92	24,067
3/1/2019	Derek T Chalmers	CEO	Sell	9,792	$17.04	$166,855.68	943,996
2/28/2019	Frederique Ph.D. Menzaghi	SVP	Sell	1,500	$17.50	$26,250.00	142,779
2/25/2019	Frederique Ph.D. Menzaghi	SVP	Sell	2,200	$17.50	$38,500.00	144,279
2/1/2019	Derek T Chalmers	CEO	Sell	20,000	$14.99	$299,800.00	953,788
1/4/2019	Derek T Chalmers	CEO	Sell	20,000	$13.61	$272,200.00
12/28/2018	Derek T Chalmers	CEO	Sell	15,825	$12.53	$198,287.25	993,788
12/28/2018	Derek T Chalmers	CEO	Sell	15,825	$12.53	$198,287.25
12/28/2018	Frederique Ph.D. Menzaghi	SVP	Sell	4,300	$12.53	$53,879.00
12/28/2018	Frederique Ph.D. Menzaghi	SVP	Sell	4,300	$12.53	$53,879.00	146,479
12/28/2018	Mani Mohindru	CFO	Sell	4,500	$12.55	$56,475.00	8,026
12/28/2018	Mani Mohindru	CFO	Sell	4,500	$12.55	$56,475.00
12/28/2018	Scott Terrillion	Insider	Sell	3,100	$12.51	$38,781.00	6,386
12/28/2018	Scott Terrillion	Insider	Sell	3,100	$12.51	$38,781.00
11/15/2018	Mani Mohindru	CFO	Sell	16,042	$18.50	$296,777.00
11/1/2018	Derek T Chalmers	CEO	Sell	20,000	$18.78	$375,600.00	991,392
11/1/2018	Frederique Ph.D. Menzaghi	SVP	Sell	3,000	$18.77	$56,310.00	145,000
10/17/2018	Joseph William Stauffer	Insider	Sell	11,442	$20.13	$230,327.46	2,970
10/17/2018	Mani Mohindru	CFO	Sell	16,042	$20.19	$323,887.98	16,042
10/1/2018	Derek T Chalmers	CEO	Sell	20,000	$23.79	$475,800.00
10/1/2018	Frederique Ph.D. Menzaghi	SVP	Sell	3,000	$23.99	$71,970.00
9/4/2018	Derek T Chalmers	CEO	Sell	20,000	$19.71	$394,200.00	1,031,392
9/4/2018	Frederique Ph.D. Menzaghi	SVP	Sell	3,000	$19.81	$59,430.00	98,000
8/20/2018	Frederique Ph.D. Menzaghi	SVP	Sell	3,000	$18.89	$56,670.00	101,000
7/10/2018	Derek T Chalmers	CEO	Sell	20,000	$20.64	$412,800.00	1,051,392
7/2/2018	Frederique Ph.D. Menzaghi	SVP	Sell	3,000	$19.00	$57,000.00	104,000

SEC Filings (Institutional Ownership Changes) for Cara Therapeutics (NASDAQ:CARA)

64.66% of Cara Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cara Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/19/2021	Squarepoint Ops LLC	10,664	$0.23M	0.0%	N/A	0.021%
5/18/2021	Disciplined Growth Investors Inc. MN	593,483	$12.89M	0.3%	-14.0%	1.186%
5/18/2021	Morgan Stanley	233,168	$5.06M	0.0%	+77.6%	0.466%
5/18/2021	Cubist Systematic Strategies LLC	56,115	$1.22M	0.0%	+37.1%	0.112%
5/17/2021	PDT Partners LLC	65,067	$1.41M	0.1%	-10.6%	0.130%
5/17/2021	AQR Capital Management LLC	10,020	$0.22M	0.0%	N/A	0.020%
5/17/2021	Royal Bank of Canada	4,644	$0.10M	0.0%	+67.6%	0.009%
5/17/2021	Price T Rowe Associates Inc. MD	2,299,299	$49.92M	0.0%	-5.3%	4.594%
5/17/2021	Janus Henderson Group PLC	170,475	$3.70M	0.0%	N/A	0.341%
5/17/2021	Nuveen Asset Management LLC	615,417	$13.36M	0.0%	+64.1%	1.230%
5/17/2021	Goldman Sachs Group Inc.	442,989	$9.62M	0.0%	-26.3%	0.885%
5/14/2021	Prosight Management LP	100,000	$2.17M	1.8%	-66.0%	0.200%
5/14/2021	Dimensional Fund Advisors LP	63,369	$1.37M	0.0%	-7.8%	0.127%
5/14/2021	First Manhattan Co.	2,169,351	$47.10M	0.2%	-18.4%	4.334%
5/14/2021	UBS Asset Management Americas Inc.	60,586	$1.32M	0.0%	+1.7%	0.121%
5/14/2021	Stifel Financial Corp	90,508	$1.97M	0.0%	-1.3%	0.181%
5/14/2021	Credit Suisse AG	40,667	$0.88M	0.0%	-18.5%	0.081%
5/14/2021	Quantbot Technologies LP	3,062	$66K	0.0%	+3,982.7%	0.006%
5/13/2021	RHO Capital Partners Inc.	2,549,058	$55.34M	5.3%	-8.9%	5.093%
5/13/2021	SG Americas Securities LLC	54,433	$1.18M	0.0%	-63.9%	0.109%
5/13/2021	Barclays PLC	39,914	$0.87M	0.0%	+140.6%	0.080%
5/13/2021	Renaissance Technologies LLC	261,450	$5.68M	0.0%	-6.2%	0.522%
5/13/2021	Penserra Capital Management LLC	311,713	$6.77M	0.1%	+172.9%	0.623%
5/13/2021	Bank of New York Mellon Corp	169,627	$3.68M	0.0%	-4.8%	0.339%
5/13/2021	Citigroup Inc.	6,417	$0.14M	0.0%	-48.7%	0.013%
5/13/2021	Martingale Asset Management L P	11,435	$0.25M	0.0%	N/A	0.023%
5/13/2021	Bank of Montreal Can	8,004	$0.22M	0.0%	-28.5%	0.016%
5/13/2021	Allianz Asset Management GmbH	14,909	$0.32M	0.0%	N/A	0.030%
5/12/2021	Northern Trust Corp	490,892	$10.66M	0.0%	-6.8%	0.981%
5/12/2021	Geode Capital Management LLC	721,938	$15.67M	0.0%	+6.8%	1.443%
5/12/2021	Pinnacle Associates Ltd.	344,651	$7.48M	0.1%	-7.6%	0.689%
5/12/2021	Wellington Shields Capital Management LLC	108,550	$2.36M	0.2%	N/A	0.217%
5/12/2021	UBS Group AG	18,808	$0.41M	0.0%	-32.2%	0.038%
5/11/2021	Aigen Investment Management LP	14,171	$0.31M	0.0%	-64.2%	0.028%
5/11/2021	Acadian Asset Management LLC	6,630	$0.15M	0.0%	N/A	0.013%
5/11/2021	Davy Global Fund Management Ltd	55,397	$1.20M	0.2%	+222.4%	0.111%
5/11/2021	Alpine Woods Capital Investors LLC	60,808	$1.32M	0.1%	+5.0%	0.122%
5/11/2021	Vontobel Holding Ltd.	10,000	$0.22M	0.0%	N/A	0.020%
5/11/2021	Silvant Capital Management LLC	9,676	$0.21M	0.0%	N/A	0.019%
5/10/2021	Russell Investments Group Ltd.	56,599	$1.23M	0.0%	-39.2%	0.113%
5/10/2021	Kestra Advisory Services LLC	11,103	$0.24M	0.0%	-19.7%	0.022%
5/10/2021	State Board of Administration of Florida Retirement System	59,212	$1.29M	0.0%	+227.8%	0.118%
5/7/2021	BlackRock Inc.	3,686,965	$80.04M	0.0%	+1.5%	7.368%
5/7/2021	Cambridge Investment Research Advisors Inc.	13,332	$0.29M	0.0%	+28.0%	0.027%
5/7/2021	BNP Paribas Arbitrage SA	16,364	$0.36M	0.0%	+26.6%	0.033%
5/7/2021	Cypress Capital Management LLC WY	72,315	$1.57M	1.4%	-11.6%	0.145%
5/7/2021	Swiss National Bank	108,200	$2.35M	0.0%	+7.3%	0.216%
5/6/2021	Arizona State Retirement System	13,781	$0.30M	0.0%	+6.8%	0.028%
5/6/2021	Rhumbline Advisers	53,569	$1.16M	0.0%	-6.1%	0.107%
5/4/2021	Victory Capital Management Inc.	45,218	$0.98M	0.0%	+19.0%	0.090%
5/3/2021	Chartwell Investment Partners LLC	14,083	$0.31M	0.0%	N/A	0.028%
5/3/2021	The Manufacturers Life Insurance Company	24,100	$0.52M	0.0%	-5.7%	0.048%
4/30/2021	Virginia Retirement Systems ET AL	38,900	$0.85M	0.0%	+42.0%	0.078%
4/27/2021	State of New Jersey Common Pension Fund D	111,153	$2.41M	0.0%	-27.6%	0.223%
4/26/2021	Assenagon Asset Management S.A.	63,882	$1.39M	0.0%	+80.7%	0.128%
4/23/2021	Strs Ohio	2,200	$47K	0.0%	N/A	0.004%
4/15/2021	Rothschild Investment Corp IL	39,000	$0.85M	0.1%	+7.1%	0.078%
4/15/2021	DnB Asset Management AS	17,210	$0.37M	0.0%	-10.4%	0.035%
4/8/2021	Baldwin Brothers Inc. MA	15,327	$0.33M	0.0%	-6.1%	0.031%
4/5/2021	Woodstock Corp	30,149	$0.66M	0.1%	+62.7%	0.060%
3/8/2021	Dimensional Fund Advisors LP	68,753	$1.04M	0.0%	+2.5%	0.138%
2/25/2021	Dimensional Fund Advisors LP	68,753	$1.04M	0.0%	+2.5%	0.138%
2/25/2021	Hsbc Holdings PLC	12,888	$0.20M	0.0%	N/A	0.026%
2/23/2021	Principal Financial Group Inc.	10,423	$0.16M	0.0%	N/A	0.021%
2/19/2021	JPMorgan Chase & Co.	98,521	$1.49M	0.0%	-2.7%	0.198%
2/17/2021	Freedman Financial Associates Inc.	5,400	$82K	0.1%	N/A	0.011%
2/16/2021	Nuveen Asset Management LLC	374,936	$5.67M	0.0%	-33.2%	0.752%
2/16/2021	Captrust Financial Advisors	3,000	$45K	0.0%	+20.0%	0.006%
2/16/2021	Price T Rowe Associates Inc. MD	2,429,235	$36.75M	0.0%	-23.6%	4.875%
2/16/2021	Virginia Retirement Systems ET AL	27,400	$0.42M	0.0%	N/A	0.055%
2/16/2021	New York Life Investments Alternatives	17,985	$0.27M	0.2%	N/A	0.036%
2/16/2021	ETF Managers Group LLC	434,527	$6.57M	0.1%	-32.8%	0.872%
2/16/2021	Engineers Gate Manager LP	27,330	$0.41M	0.0%	+2.6%	0.055%
2/16/2021	Charles Schwab Investment Management Inc.	279,758	$4.23M	0.0%	+0.5%	0.561%
2/13/2021	American International Group Inc.	23,928	$0.36M	0.0%	-2.8%	0.048%
2/12/2021	Stifel Financial Corp	91,692	$1.39M	0.0%	+4.8%	0.184%
2/12/2021	Penserra Capital Management LLC	114,205	$1.73M	0.0%	+73.2%	0.229%
2/12/2021	Raymond James Financial Services Advisors Inc.	11,471	$0.17M	0.0%	-6.2%	0.023%
2/12/2021	The Manufacturers Life Insurance Company	25,567	$0.39M	0.0%	+3.1%	0.051%
2/12/2021	Credit Suisse AG	49,878	$0.76M	0.0%	+47.1%	0.100%
2/12/2021	Virtus ETF Advisers LLC	19,799	$0.30M	0.1%	-3.3%	0.040%
2/11/2021	Northern Trust Corp	526,543	$7.97M	0.0%	-1.2%	1.057%
2/11/2021	Barclays PLC	16,589	$0.25M	0.0%	-25.0%	0.033%
2/10/2021	Rhumbline Advisers	57,036	$0.86M	0.0%	+3.9%	0.114%
2/10/2021	Renaissance Technologies LLC	278,714	$4.22M	0.0%	-6.8%	0.559%
2/9/2021	Wells Fargo & Company MN	126,688	$1.92M	0.0%	+17.4%	0.254%
2/9/2021	Bank of New York Mellon Corp	178,248	$2.70M	0.0%	-1.6%	0.358%
2/9/2021	ProShare Advisors LLC	16,809	$0.25M	0.0%	+33.4%	0.034%
2/8/2021	Alliancebernstein L.P.	49,000	$0.74M	0.0%	-20.6%	0.098%
2/8/2021	Russell Investments Group Ltd.	93,162	$1.41M	0.0%	+45.8%	0.187%
2/5/2021	BlackRock Inc.	3,632,266	$54.96M	0.0%	-1.7%	7.289%
2/5/2021	Aperio Group LLC	10,014	$0.15M	0.0%	N/A	0.020%
2/5/2021	SG Americas Securities LLC	150,901	$2.28M	0.0%	+13.4%	0.303%
2/4/2021	Cambridge Investment Research Advisors Inc.	10,416	$0.16M	0.0%	N/A	0.021%
2/4/2021	State of Wisconsin Investment Board	58,700	$0.89M	0.0%	-11.1%	0.118%
2/3/2021	State of New Jersey Common Pension Fund D	153,536	$2.32M	0.0%	+2.9%	0.308%
2/1/2021	Alpine Woods Capital Investors LLC	57,927	$0.88M	0.1%	+217.6%	0.116%
2/1/2021	Victory Capital Management Inc.	38,005	$0.58M	0.0%	-5.3%	0.076%
2/1/2021	Assenagon Asset Management S.A.	35,359	$0.54M	0.0%	-78.5%	0.071%
1/30/2021	Davy Global Fund Management Ltd	17,184	$0.26M	0.1%	N/A	0.034%

Data available starting January 2016

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.

Today's Range

Now: $14.45

$14.09

$14.60

50 Day Range

MA: $17.05

$12.38

$28.52

52 Week Range

Now: $14.45

$11.80

$29.65

Volume

20,297 shs

Average Volume

944,263 shs

Market Capitalization

$723.25 million

P/E Ratio

62.83

Dividend Yield

N/A

Beta

1.13

Who are the company insiders with the largest holdings of Cara Therapeutics?

Cara Therapeutics' top insider investors include:

Derek T Chalmers (CEO)
Frederique PhD Menzaghi (Insider)
Frederique PhD Menzaghi (SVP)
Scott Terrillion (Insider)
Mani Mohindru (CFO)
Joana Goncalves (Insider)
Martin Vogelbaum (Director)
Christopher Posner (Director)
Jeffrey L Ives (Director)

Who are the major institutional investors of Cara Therapeutics?

Cara Therapeutics' top institutional investors include:

BlackRock Inc. — 7.37%
RHO Capital Partners Inc. — 5.09%
Price T Rowe Associates Inc. MD — 4.59%
First Manhattan Co. — 4.33%
Geode Capital Management LLC — 1.44%
Nuveen Asset Management LLC — 1.23%

Which institutional investors are selling Cara Therapeutics stock?

During the last quarter, CARA stock was sold by these institutional investors:

First Manhattan Co.
RHO Capital Partners Inc.
Prosight Management LP
Goldman Sachs Group Inc.
Price T Rowe Associates Inc. MD
SG Americas Securities LLC
Disciplined Growth Investors Inc. MN
State of New Jersey Common Pension Fund D

During the previous year, company insiders that have sold Cara Therapeutics company stock include:

Derek T Chalmers (CEO)
Frederique PhD Menzaghi (Insider)
Frederique PhD Menzaghi (SVP)
Scott Terrillion (Insider)
Mani Mohindru (CFO)
Joana Goncalves (Insider)

Which institutional investors are buying Cara Therapeutics stock?

During the previous quarter, CARA stock was purchased by institutional investors including:

Nuveen Asset Management LLC
Penserra Capital Management LLC
Janus Henderson Group PLC
Wellington Shields Capital Management LLC
Morgan Stanley
BlackRock Inc.
Geode Capital Management LLC
State Board of Administration of Florida Retirement System

The BIG CON “Screwing Americans”

From Stansberry | Ad

The rich and powerful are thrilled... Inflation is GREAT for them. It’s everyone else who’ll get screwed. But according to an ex-Wall Street vet, there’s actually a way for YOU to turn the tables – just make this one move before July 29th.

Click here to see why